News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
747,964 Results
Type
Article (52115)
Company Profile (360)
Press Release (695488)
Multimedia
Podcasts (108)
Webinars (16)
Section
Business (213561)
Career Advice (2144)
Deals (36667)
Drug Delivery (107)
Drug Development (84414)
Employer Resources (178)
FDA (17036)
Job Trends (15465)
News (360456)
Policy (33982)
Tag
Academia (2834)
Academic (1)
Accelerated approval (11)
Adcomms (27)
Allergies (99)
Alliances (53145)
ALS (116)
Alzheimer's disease (1487)
Antibody-drug conjugate (ADC) (181)
Approvals (17013)
Artificial intelligence (349)
Autoimmune disease (33)
Automation (18)
Bankruptcy (369)
Best Places to Work (12013)
BIOSECURE Act (20)
Biosimilars (125)
Biotechnology (255)
Bladder cancer (98)
Brain cancer (35)
Breast cancer (378)
Cancer (3019)
Cardiovascular disease (220)
Career advice (1795)
Career pathing (31)
CAR-T (206)
CDC (32)
Cell therapy (559)
Cervical cancer (23)
Clinical research (68996)
Collaboration (1072)
Company closure (3)
Compensation (697)
Complete response letters (27)
COVID-19 (2781)
CRISPR (66)
C-suite (341)
Cystic fibrosis (118)
Data (3049)
Decentralized trials (2)
Denatured (39)
Depression (65)
Diabetes (353)
Diagnostics (6762)
Digital health (24)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (150)
Drug pricing (131)
Drug shortages (30)
Duchenne muscular dystrophy (127)
Earnings (89481)
Editorial (44)
Employer branding (22)
Employer resources (155)
Events (119940)
Executive appointments (885)
FDA (18728)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (981)
Gene editing (145)
Generative AI (29)
Gene therapy (416)
GLP-1 (819)
Government (4680)
Grass and pollen (5)
Guidances (181)
Healthcare (19760)
HIV (42)
Huntington's disease (31)
IgA nephropathy (40)
Immunology and inflammation (163)
Immuno-oncology (10)
Indications (40)
Infectious disease (2959)
Inflammatory bowel disease (154)
Inflation Reduction Act (11)
Influenza (64)
Intellectual property (123)
Interviews (336)
IPO (17041)
IRA (45)
Job creations (3864)
Job search strategy (1521)
Kidney cancer (14)
Labor market (52)
Layoffs (527)
Leadership (19)
Legal (8235)
Liver cancer (84)
Longevity (12)
Lung cancer (431)
Lymphoma (215)
Machine learning (11)
Management (62)
Manufacturing (409)
MASH (92)
Medical device (14234)
Medtech (14239)
Mergers & acquisitions (20359)
Metabolic disorders (879)
Multiple sclerosis (100)
NASH (16)
Neurodegenerative disease (125)
Neuropsychiatric disorders (34)
Neuroscience (2195)
NextGen: Class of 2025 (6944)
Non-profit (4687)
Now hiring (47)
Obesity (443)
Opinion (238)
Ovarian cancer (103)
Pain (106)
Pancreatic cancer (124)
Parkinson's disease (192)
Partnered (22)
Patents (309)
Patient recruitment (168)
Peanut (53)
People (60367)
Pharmaceutical (75)
Pharmacy benefit managers (21)
Phase I (21717)
Phase II (30347)
Phase III (22508)
Pipeline (1663)
Policy (208)
Postmarket research (2645)
Preclinical (9562)
Press Release (71)
Prostate cancer (145)
Psychedelics (39)
Radiopharmaceuticals (274)
Rare diseases (486)
Real estate (6318)
Recruiting (68)
Regulatory (23635)
Reports (50)
Research institute (2553)
Resumes & cover letters (370)
Rett syndrome (9)
RNA editing (10)
RSV (52)
Schizophrenia (91)
Series A (168)
Series B (112)
Service/supplier (15)
Sickle cell disease (67)
Special edition (20)
Spinal muscular atrophy (156)
Sponsored (34)
Startups (3894)
State (2)
Stomach cancer (17)
Supply chain (78)
Tariffs (57)
The Weekly (67)
Vaccines (839)
Venture capital (55)
Weight loss (274)
Women's health (50)
Worklife (16)
Date
Today (67)
Last 7 days (385)
Last 30 days (1940)
Last 365 days (32351)
2025 (17385)
2024 (36639)
2023 (41500)
2022 (52824)
2021 (57456)
2020 (56049)
2019 (48868)
2018 (36853)
2017 (34053)
2016 (33732)
2015 (39899)
2014 (33529)
2013 (29024)
2012 (31215)
2011 (31627)
2010 (29628)
Location
Africa (788)
Alabama (64)
Alaska (7)
Arizona (255)
Arkansas (14)
Asia (41964)
Australia (7089)
California (7620)
Canada (2383)
China (700)
Colorado (328)
Connecticut (332)
Delaware (202)
Europe (92913)
Florida (1131)
Georgia (258)
Hawaii (1)
Idaho (63)
Illinois (666)
India (27)
Indiana (369)
Iowa (17)
Japan (233)
Kansas (113)
Kentucky (31)
Louisiana (15)
Maine (73)
Maryland (1047)
Massachusetts (5769)
Michigan (268)
Minnesota (463)
Mississippi (3)
Missouri (96)
Montana (31)
Nebraska (26)
Nevada (81)
New Hampshire (72)
New Jersey (2115)
New Mexico (30)
New York (2135)
North Carolina (1143)
North Dakota (10)
Northern California (3325)
Ohio (241)
Oklahoma (17)
Oregon (37)
Pennsylvania (1636)
Puerto Rico (18)
Rhode Island (37)
South America (1193)
South Carolina (35)
South Dakota (1)
Southern California (2842)
Tennessee (128)
Texas (1157)
United States (28425)
Utah (226)
Virginia (189)
Washington D.C. (73)
Washington State (651)
West Virginia (4)
Wisconsin (72)
747,964 Results for "stemedica cell technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Diabetes
Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain
While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target population and Vertex’s execution hang over the cell therapy’s commercial potential.
June 23, 2025
·
2 min read
·
Tristan Manalac
Regulatory
RFK Jr. Joins Deputies in Voicing Support for Regulatory Flexibility for Cell and Gene Therapies
In a roundtable event on Thursday, HHS Secretary Robert F. Kennedy Jr. said his office will work to eliminate barriers that keep cell and gene therapies from the market.
June 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
May 29, 2025
·
4 min read
Press Releases
Unlocking the Future of Personalized Medicine with iPS Cell Technology
April 24, 2025
·
3 min read
Press Releases
Portal Biotechnologies Awarded $8M DARPA Contract to Increase Access to Cell Therapy via a Portable, Red Blood Cell Engineering Device for Rapid Point-of-Care Production and Treatment
June 24, 2025
·
3 min read
Press Releases
Hemostemix’s VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!
Florida SB 1768 Becomes Law: Hemostemix Inc. Begins Commercial Offering of ACP-01 (VesCell) for Ischemic Pain Treatments in Florida.
July 2, 2025
·
8 min read
Mergers & acquisitions
AstraZeneca Makes Potential $1B Cell Therapy Play in EsoBiotec Buy
AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and Gracell Biotechnologies.
March 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025
·
5 min read
Press Releases
SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations at ASCO Congress 2025
May 23, 2025
·
5 min read
IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES
Cell and Gene Therapy Sector Sees 30% Investment Surge Despite Market Challenges
Industry updates and investment insights—including investor behavior and fundraising advice—were among the topics experts explored at Charles River Laboratories’ 2025 Cell & Gene Therapy Summit.
March 31, 2025
·
5 min read
·
BioSpace Insights
1 of 74,797
Next
